Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study.
BACKGROUND It is unclear whether early initiation of low-dose pravastatin therapy can reduce the occurrence of major adverse cardiac events after acute myocardial infa rct ion ( AMI ) . METHODS AND RESULTS The study group comprised 353 patients with AMI who had plasma total cholesterol levels of 200 - 250 mg/dl and triglyceride levels < 300 mg/dl . The patients were r and omly assigned to either receive pravastatin ( 10 mg/daily , n=176 ) or not ( n=177 ) . The primary endpoint was a composite of death , nonfatal myocardial infa rct ion ( MI ) , unstable angina ( UA ) , stroke , revascularization , and rehospitalization because of other cardiovascular disease . The follow-up period was 9 months . The primary endpoint occurred in 31 patients ( 17.9 % ) in the pravastatin group and 55 patients ( 31.4 % ) in the non-pravastatin group ( relative risk , 0.56 ; 95 % confidence interval , 0.36 - 0.87 ) . There were no significant differences in the risk of death , nonfatal MI , UA , and stroke between the 2 groups , although the pravastatin group had a lower risk of need for revascularization . CONCLUSION For patients with AMI , early and low-dose pravastatin therapy ( 10 mg/daily ) reduces recurrent major adverse cardiac events , mostly the requirement for revascularization
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .